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Abstract
Chronic rotator cuff (RC) tears are characterized by retraction, fat accumula-
tion, and atrophy of the affected muscle. These features pose an intractable
problem for surgical repair and subsequent recovery, and their prevention
may be easier than reversal. Using an established ovine model, we tested the
hypothesis that inhibition of the protease calpain mitigates m. infraspinatus
atrophy by preservation of the myofibers’ structural anchors in the sar-
colemma (the costameres). Already 2 weeks of distal tendon release led to a
reduction in muscle volume (11.6  9.1 cm3, P = 0.038) and a 8.3% slow-
to-fast shift of the fiber area (P = 0.046), which were both entirely abolished
by chronic local administration of the calpain inhibitor calpeptin alone, and
in combination with sildenafil. Calpain inhibition blunted the retraction of
the muscle-tendon unit by 0.8–1.0 cm (P = 0.020) compared with the control
group, and prevented cleavage of the costameric protein talin. Calpain 1 and
2 protein levels increased in the medicated groups after 4 weeks, counteracting
the efficacy of calpeptin. Hence atrophic changes emerged after 4 weeks
despite ongoing treatment. These findings suggest that the early muscular
adaptations in the specific case of RC tear in the ovine model are indistin-
guishable from the atrophy and slow-to-fast fiber transformation observed
with conventional unloading and can be prevented for 2 weeks. Concluding,
calpain is a potential target to extend the temporal window for reconstruction
of the ruptured RC tendon before recovery turns impossible.
Introduction
Chronic rotator cuff (RC) tendon tears are among the
most frequent causes of shoulder dysfunction (Milgrom
et al. 1995; Sher et al. 1995) leading to various functional
deficits including weakness and limited range of motion
(Duckworth et al. 1999). These tears often occur unno-
ticed and therefore remain untreated for months or years
until they create functional impairment or pain (Milgrom
et al. 1995; Yamaguchi et al. 2006). At this point, the
affected RC muscle is already shortened, contractile tissue
is lost and muscle volume predominantly consists of fat
and connective tissue; a transformation that substantially
complicates treatment or even renders it impossible (Bar-
tolozzi et al. 1994; Goutallier et al. 1994; Gladstone et al.
2007). A time line of the progression of atrophy and
degeneration in man is essentially unavailable and
researchers are prompted to use animal models to
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characterize muscle loss in chronic RC tear. The ovine
model is considered valid as relevant parameters like fiber
type composition (Suzuki 1995; Lovering and Russ 2008)
or changes in fat fraction (Pfirrmann et al. 2004; Ruoss
et al. 2017) are comparable to changes observed in
human RC muscles, as opposed to small animal models,
which do not present these features (Lebaschi et al. 2016;
Rui et al. 2016). Studies in sheep have shown that muscle
atrophy after RC tear is already present after 2 weeks and
once a chronic transformation is fully established (i.e.,
atrophy and intramuscular fat content compare to
chronic human RC tear), reversal fails despite gradual
mechanical reloading and/or anabolic steroid treatment
(Gerber et al. 2004, 2012; Ruoss et al. 2017). Thus, suc-
cessful prevention of early adaptations to tear-induced
unloading could extend the window of opportunity for
successful surgical repair and recovery of muscle function.
Early adaptation to unloading is characterized by decreas-
ing muscle volume with little to no fat accumulation
(Rowshan et al. 2010; Uhthoff et al. 2014; Ruoss et al.
2017). Loss of contractile tissue leads to both radial and
longitudinal atrophy, the latter leading to the clinical phe-
nomenon of “myotendinous retraction” which is related
to serial removal of sarcomeres from myofibrils (Jamali
et al. 2000; Ward et al. 2010). This process is initiated by
specific Ca2+-activated proteases, the calpains, which
release sarcomeres by attacking their structural anchors at
the Z-disk so that they can be quantitatively degraded by
the proteasome (Bullard et al. 1990; Alderton and Stein-
hardt 2000; Tidball and Spencer 2002; Goll et al. 2008;
Shenkman et al. 2015). One of these anchors is the costa-
mere, a subsarcolemmal protein complex that couples the
sarcomere with the extracellular matrix (Ervasti 2003).
Among other costameric proteins, talin, vinculin, focal
adhesion kinase (FAK), and its phosphorylation at the
tyrosine 397 site (FAK-pY397) are critical for costamere
turnover and integrity. These proteins are also excellent
calpain substrates. As an example, calpain can very
rapidly cleave talin creating 190 kDa C-terminal and
47 kDa N-terminal fragments that are no longer func-
tional (Goll et al. 2003). Calpain activity is triggered by
increased intracellular Ca2+ concentration. Likewise coun-
ter-regulation is observed by a broad variety of molecules,
for example, its specific endogenous inhibitor calpastatin,
nitric oxide (NO) or synthetic inhibitors like calpeptin,
all of them having shown to save muscle protein com-
pared with an untreated control (Alderton and Steinhardt
2000; Koh and Tidball 2000; Tidball and Spencer 2002;
Goll et al. 2003; Fareed et al. 2006; Shenkman et al.
2015). In the ovine model of RC tear, loss of contractile
tissue is associated with an increase in the 190 kDa prote-
olytic fragments of talin, suggesting a potential role of
calpain (Ruoss et al. 2017). However, no causal
connection could so far be established among calpain
activity, costamere cleavage, and loss of contractile tissue.
It was therefore the aim of this study to test the following
hypotheses: First, release of a rotator cuff tendon leads to
increased calpain activity in the ovine model. Second, inhi-
bition of calpain activity with calpeptin and the NO pro-
moter sildenafil decreases costamere cleavage and
consequently muscle atrophy and myotendinous retraction.
Methods
Ethical approval
Experiments were approved by the Veterinary Office of
the Canton of Zurich, Switzerland (No. ZH219/2014) and
performed according to the Swiss law of animal welfare
(TSchG455). Animal care and surgeries were performed
by veterinarians at the Animal Hospital of the University
of Zurich and animals’ pain and suffering were mini-
mized by appropriate anesthesia and analgesia described
previously (Gerber et al. 2004). Food and water were
available ad libitum.
Experimental design
In 18 female Swiss Alpine sheep (age: 26.7  1.4 months
[mean  SD]), distal tendon tear of the m. infraspinatus
was simulated by osteotomy of the greater tuberosity of the
right shoulder as described previously (Gerber et al. 2015).
Six sheep received the calpain inhibitor calpeptin (group
CALP, body mass: 63.5  5.5 kg). Another six sheep were
administered daily doses of sildenafil additionally to calpep-
tin (group CALPSILD, body mass: 62.1  1.9 kg) and the
remaining six sheep served as CONTROL group by receiving
the calpeptin vehicle (body mass: 63.3  3.4 kg). Prior to
tendon release (PRE) and after 2, 4, and 6 weeks, the right
m. infraspinatus was biopsied to determine tissue composi-
tion, fiber type distribution, protein expression, and calpain
activity. Furthermore, computed tomography (CT) scans
were performed to assess muscle volume, length, and CSA at
30 min, 2, 4, and 6 weeks. The left shoulder was not manip-
ulated until a single biopsy was taken before euthanasia at
6 weeks and served as a group-internal contralateral control
(CC). One sheep of the CALP group was euthanized at
2 weeks and excluded from analysis due to a fracture of the
greater tuberosity. No further complications occurred and
all other sheep were euthanized at 6 weeks.
Administration of calpain inhibitor and
sildenafil
Calpeptin (#ab120804, Abcam, Cambridge, UK) was dis-
solved in 75% dimethyl sulfoxide (DMSO) to a final
2018 | Vol. 6 | Iss. 21 | e13833
Page 2
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Calpeptin Delays Atrophy S. Ruoss et al.
concentration of 12.5 mg mL1 and administered locally
by a 2 mL Alzet osmotic pump (2ML4, Durect Corp.,
Cupertino CA) modified with a polyethylene catheter
(PE-60, Durect Corp.) attached to the PEEKTM flow mod-
erator (Victrex PLC, Thornton Cleveleys, UK). Constant
administration (pump flow rate: 2.5 lL/h, calpeptin daily
dose: 0.75 mg, DMSO daily dose: 45 lL) was verified by
recollecting the leftover volume after the pump was
removed from the sheep.
One daily dose of 50 mg sildenafil (Pfizer, New York)
was administered in tablet form in the mornings. Entry
through the gastrointestinal tract was confirmed by
detecting increased intraocular pressure (Gerometta et al.
2010) using a TonoVet tonometer (Icare, Helsinki, Fin-
land) in patient mode “p” according to the user manual.
Values of oculus dexter (OD) and oculus sinister (OS)
were pooled.
Tendon release and implantation of the
osmotic pump
The distal tendon of the right m. infraspinatus was
released by chipping the bone piece of the greater
tuberosity where the tendon inserts using an oscillating
saw. To avoid spontaneous attachment, the tendon and
bone chip were wrapped in a silicone tube as described
previously (Gerber et al. 2015).
The Alzet pump was implanted at the caudal aspect
of the scapular spine, cranially of the right m. infraspina-
tus and approximately 5 cm dorsal to the acromion. In
detail, a 0.5 cm incision was made right at the crest of
the scapular spine using a scalpel blade and a pocket was
created with a periosteal elevator, so that the pump could
be inserted and moved dorsally. The exit point of the
catheter was distal, 6 cm dorsal from the acromion, and
the pump was turned so that the natural curvature of the
catheter pointed towards the muscle. A small incision was
made into the muscle at approximately 3 cm distal to the
scapular spine using a small curved mosquito clamp. A
tiny tunnel was pierced through which the catheter was
pulled into the muscle belly without being kinked. The
catheter outlet was left freely in the distal third of the lat-
eral aspect of the muscle. The pump was implanted in all
sheep, filled with either calpeptin or vehicle only. To
cover a time course of 6 weeks, the pump was replaced at
2 weeks as its volume allowed drug delivery for up to
4 weeks only. All surgeries were performed blinded.
Sampling of muscle tissue
Muscle biopsies were collected intraoperatively with the
sheep under general anesthesia. Approximately 50 mg of
the distal, lateral third of m. infraspinatus was extracted
using a 5 mm Bergstroem needle (Dixons Surgical Instru-
ments LTD, Wickford), immediately frozen in liquid
nitrogen cooled isopentane and stored at 80°C until
analysis.
Muscle volume, length, and cross-sectional
area
CT scans (Somatom ART; Siemens Medical Solutions,
Erlangen, Germany) of both shoulders were performed
with the sheep in supine position, under general anesthe-
sia. The baseline measurement was conducted directly
after surgery (i.e., 30 min after tendon release) and all
follow-up scans were performed before surgery. Axial
images (slice thickness: 1 mm, tube voltage: 120 kV, tube
current: 200 mA/slice) were acquired and reconstructed
in the coronal plane. All measurements were performed
blinded. Infraspinatus muscle volume and CSA were
assessed on both sides using the free-hand ROI (region of
interest) tool in the Merlin PACS software (v5.121375,
Ph€onix, Freiburg i. Br., Germany) as follows: Muscle vol-
ume was calculated from areas assessed on axial images at
every 4 mm by drawing a ROI surrounding the outer
muscle contour. CSA was measured on a standardized
coronal slice defined as lying 1 cm anterior to the ante-
rior end of the pump (where the catheter outlet was
expected). Muscle length was measured at its longest
diameter on axial slices from posterior to anterior includ-
ing the distal tendon stump, but excluding the bone chip
on the operated side, or until bone insertion on the con-
tralateral side, respectively.
Tissue distribution
Two consecutive 12 lm thin sections were stained for
either contractile and connective tissue using the Goldner
trichrome technique (Goldner 1938) or for fat with oil
red O as described (Ruoss et al. 2017). Total area
(=100%) and fat area percentage were measured on the
oil red O staining and contractile tissue area percentage
on the Goldner-stained section using Image J (v1.48v,
National Institutes of Health) according to a standard
procedure (Ruoss et al. 2017). The area percentage of
non-fatty connective tissue was calculated as “total area -
(fatty tissue area + contractile tissue area)”. The fiber type
distribution was assessed by immunofluorescence staining
of the slow and fast types myosin heavy chain (MyHC)
isoforms 1 and 2, respectively, (protocol described previ-
ously (Ruoss et al. 2017)), using a mouse a-MyHC-1
(#MAB1628, Millipore Corp., Temecula, 1:100) and a
rabbit a-MyHC-2 primary antibody (#ab91506,
Abcam1:100), whereas fibers stained for both isoforms
were specified as hybrid fibers. As secondary antibodies,
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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the a-mouse Alexa Fluor 488 #A11017 and anti-rabbit
Alexa Fluor 555 #A21428 (Thermo Fisher Scientific,
Waltham) were used 1:200. All measurements were per-
formed blinded.
We have recently shown in this model that the sole
consideration of a % change in muscle composition may
be misleading if the absolute volume to which it is
related, undergoes alterations, too (Ruoss et al. 2017).
Therefore, we also report approximate volumes of the
assessed tissue and fiber types. They were calculated by
extrapolation of the area percentages from histological
results to the respective muscle volumes assessed on the
CT scans.
Calpain activity
Approximately 5 mg of tissue was homogenized in
115 lL KH2PO4. (0.1 mol L
1, pH = 7.2), of which
25 lg of total protein in KH2PO4 was loaded on a 96-
well plate (#655900, Greiner Bio-One, Kremsm€unster,
Austria) and filled up to a total volume of 48 lL with
reaction buffer (60 mmol L1 imidazole, pH = 7.3; 2%
DMSO/MetOH; 2.5 mmol L1 b-mercaptoethanol;
ddH2O) containing 250 lmol L
1 Suc-Leu-Tyr-Amino-
methylcoumarin (#I1355, Bachem, Bubendorf, Switzer-
land) as substrate. A standard curve of free
aminomethylcoumarin (AMC; #BML-KI144, Enzo Life
Sciences, Farmingdale NY) in reaction buffer was loaded
on every plate. The fluorescence excitation (340/30 nm
filter) was performed on a Synergy HT plate reader using
Gen5 software (v2.09, BioTek Instruments, Winooski VT)
and emission (460/40 nm filter) was recorded every
10 min. Enzymatic activity of calpain is expressed as slope
of increasing free AMC concentration over time, that was
determined from all reading points being located in the
linear phase of the parabolic curve before plateauing,
which was from 0 to 50 min for all 85 samples.
Protein levels
Western blotting was performed as described previously
(Ruoss et al. 2017). Target proteins were detected in
10 lg of total protein homogenate using the Biorad
Trans-Blot Turbo System (Biorad, Cressier, Switzerland),
only FAK-pY397 was detected in 10 lL of precipitate that
was obtained from 250 lg of total protein as described
(Ruoss et al. 2017) using 200 lg protein A-sepharose
(#P9424, Sigma-Aldrich, St. Louis) and a combination of
anti-FAK-pY397 antibodies (1 lL each, #44-624G,
Thermo Fisher Scientific, Waltham; #sc-11765-R, Santa
Cruz Biotechnology, Texas). The following primary anti-
bodies were used: rabbit a-FAK serum (1:1000) (Fluck
et al. 1999), monoclonal mouse a-talin #ab95034 (Abcam;
1:100), mouse a-vinculin serum (gift of Dr. M. A. Glu-
khova (Glukhova et al. 1990), Paris, France; 1:100), rabbit
a-calpain1 #ab28258 (Abcam; 1:2000), rabbit a-calpain2
#ab39165 (Abcam; 1:2000), and a monoclonal mouse a-
PPAR-gamma #LS-C178333 (Lifespan Biosciences Inc.,
LabForce AG, Nunnigen, Switzerland; 1: 1000). The goat
a-mouse #A9917 (Sigma-Aldrich, St. Louis; 1:20000) and
goat a-rabbit #55676 (MP Biomedicals, Ohio; 1:20000)
were used as secondary antibodies. Blotting quality and
equal loading were verified using Ponceau S staining and
target bands were quantified using the rectangular mode
in the Quantity One software (Biorad, Cressier, Switzer-
land) according to the user manual. Inter-membrane vari-
ability was controlled by dividing the signals by an
internal standard that was loaded on every gel. Afterward,
the relative changes of the signal intensities were related
to the PRE-values.
Statistics
All data are presented as mean  SD. SPSS Statistics
v22.0 (IBM, Armonk) was used to run statistical analysis.
Differences between time points and intervention groups
were detected using a split-plot ANOVA with “time
point” (PRE, 2, 4, and 6 weeks) as repeated within-sub-
jects factor and “group” (CONTROL, CALP, CALPSILD)
as between-subjects factor. Comparison with the con-
tralateral control was drawn using a split-plot ANOVA
with the repeated within-subjects factor “shoulder”
(operated, contralateral) and the between-subjects factor
“treatment.” Normal distribution was verified using a
Shapiro-Wilk test. If not normally distributed data were
detected at a single time point within the time course, the
split-plot ANOVA was still performed as it has been
shown to be robust against minor violations of normality
as long as sample size does not change (Field 2009). The
PPAR-gamma 1 and 2 PRE-values of one sheep in the
CALP group were identified as outliers, being located
more than 2.2x of the interquartile range above the upper
quartile (Hoaglin and Iglewicz 1987). These two PRE-
values were excluded from PPAR-gamma analysis. Statis-
tical significance was defined as P < 0.05.
Results
Calpeptin with and without sildenafil
administration mitigates retraction and
delays atrophy of the released rotator cuff
muscle
All intervention groups started with a similar m.
infraspinatus volume (CONTROL: 202.6  14.8 cm3;
CALP: 201.5  29.8 cm3; CALPSILD: 202.6  32.5 cm3,
2018 | Vol. 6 | Iss. 21 | e13833
Page 4
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Calpeptin Delays Atrophy S. Ruoss et al.
Figure 1A. Volumes of the contralateral m. infraspinatus
are displayed in Fig. S1A). Analysis of CT scans from
30 min, 2, 4, and 6 weeks after tendon release revealed
that calpeptin administration prevented muscle atrophy
for 2 weeks while muscle volume was lost in the CON-
TROL group (11.6  9.1 cm3, P = 0.038; Fig. 1A). The
protective effect of calpain inhibition was gone at 4 weeks
and 6 weeks as muscle atrophy was detected in all groups
compared to 30 min (4 weeks: CONTROL: 28.4 
14.6 cm3, P < 0.001; CALP: 26.2  15.0 cm3, P <
0.001; CALPSILD: 20.1  10.7 cm3, P = 0.003; 6 weeks:
CONTROL: 45.8  15.8 cm3, P < 0.001; CALP:
46.3  10.8 cm3, P < 0.001; CALPSILD: 46.7  12.0
cm3, P < 0.001; Fig. 1A). In parallel, immediate retraction
of the m. infraspinatus was diagnosed in all groups com-
pared with the contralateral side and further progressed
over the 6 weeks time course (Fig. 1B). Compared with the
CONTROL group, the muscle was significantly longer at
30 min after tendon release in the CALPSILD (+1.0 cm,
P = 0.042), but not in the CALP group (+0.9 cm,
P = 0.083); while at 4 weeks, it was significantly longer in
both CALPSILD (+0.8 cm, P = 0.040) and CALP groups
(+1.0 cm, P = 0.020; Fig. 1B). Muscle CSA assessed close
to the drug delivery site, was significantly decreased in
CONTROL and CALP (1.9  1.4 cm2, P = 0.001 and
1.7  1.1 cm2, P = 0.005, respectively), but not in the
CALPSILD group (0.8  0.9 cm2, P = 0.123) at 6 weeks
compared with 30 min after tendon release (Fig. 1C).
Figure 1. Calpain inhibition delays atrophy of rotator cuff muscle and mitigates shortening of the muscle-tendon complex. Muscle
morphometry of the operated m. infraspinatus and the contralateral control (CC) assessed at 30 min, 2, 4, and 6 weeks after surgical tendon
release. (A) Loss of muscle volume started between 2 and 4 weeks in the calpeptin-treated sheep (CALP, n = 5; CALPSILD, n = 6), while it was
already detected at 2 weeks in the CONTROL group (n = 6). (B) Calpeptin treatment acutely mitigated shortening of the muscle. (C) Muscle
cross-sectional area (CSA) did not decrease before 6 weeks. Time effects: * P < 0.05, ** P < 0.01, *** P < 0.001 versus 30 min; + P < 0.05,
++ P < 0.01, +++ P < 0.001 versus 2 weeks; & P < 0.05, &&& P < 0.001 versus 4 weeks. Group effects: # P < 0.05 versus CONTROL; P < 0.05,
$$ P < 0.001 versus operated shoulder at 30 min. Bars are means  SD.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Calpeptin delays early slow-to-fast
phenotype shift
Total contractile tissue area was not affected at 2 weeks
(Fig. 2A), but the area occupied by slow fibers signifi-
cantly decreased at 2 weeks compared with PRE in the
CONTROL group (8.3  10.7%, P = 0.046). Slow fiber
area percentage remained unchanged in the CALP
(+1.8  9.4%, P = 0.675) and CALPSILD groups
(+1.1  7.6%, P = 0.777; Fig. 2B). After 4 weeks, a rela-
tive decrease in slow fiber area percentage was detected in
all groups (CONTROL: 12.5  9.6%, P = 0.002; CALP:
11.2  4.8%, P = 0.006; CALPSILD: 10.7  7.6%,
P = 0.005; compared with the baseline) and being scaled
to a total fiber area of 100%, it is logical that these effects
were paralleled by a relative increase in the fast fiber area
percentage (Fig. 2B). Then, we extrapolated this relative
distribution to the contractile tissue volume (see
Figure 2. Tendon release leads to changes in relative contractile versus non-contractile tissue distribution and to a slow-to-fast fiber phenotype
shift, of which the latter is delayed by calpain inhibition. The distribution of different tissue types assessed prior to, and 2, 4, and 6 weeks after
tendon release. (A) Loss of contractile tissue and fibrosis were not detected before 2 weeks after tendon release. (B) Fiber type distribution
assessed on myosin heavy chain (MyHC) isoforms 1 (green, slow) and 2 (red, fast) stained sections. Hybrid fibers express both isoforms and
appear orange on the merge image. The slow-to-fast phenotype shift was detected from 2 weeks on in the CONTROL group (n = 6), but not
until 4 weeks with calpain inhibition (CALP, n = 5; CALPSILD, n = 6). Time effects: * P < 0.05, ** P < 0.01 versus PRE; + P < 0.05, ++ P < 0.01
versus 2 weeks. Columns are means + SD. Black scale bars denote 100 lm; white scale bars denote 50 lm.
2018 | Vol. 6 | Iss. 21 | e13833
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Methods) and found the increase in the fast fiber portion
not confirmed. On the contrary, fast fiber volume
remained unchanged in all groups until 4 weeks and was
significantly decreased at 6 weeks compared with baseline
(CONTROL: 23.5  28.8 cm3, P = 0.023; CALP:
32.2  11.7 cm3, P = 0.007; CALPSILD: 31.5 
22.0 cm3, P = 0.004; Fig. 3A). Slow fiber volume was
decreased at 2 weeks in the CONTROL group (8.3 
10.7 cm3, P = 0.026), but not in the calpeptin-treated
sheep (CALP: +1.8  9.4 cm3, P = 0.605; CALPSILD:
+1.1  7.6 cm3, P = 0.931) compared with PRE
(Fig. 3A). Neither the area percentage nor the volume of
slow/fast hybrid fibers were significantly increased
(Fig. 2B and 3A).
Tendon release leads to an early modulation
of fatty and non-fatty connective tissue
Fatty tissue area percentage tended to decrease over all
groups at 2 weeks (1.9  3.9%, P = 0.084, compared
with PRE). Between 2 weeks and 6 weeks, it increased in
the calpeptin-treated sheep (CALP: +4.4  4.8%,
P = 0.017; CALPSILD: +3.5  2.1%, P = 0.033; Fig. 2A).
Over all groups, fatty tissue volume was significantly lar-
ger at 6 weeks than at 2 weeks (+3.0  5.8 cm3,
P = 0.041; Fig. 3B).
The area percentage of nonfatty connective tissue
increased from 4 weeks onwards in the calpeptin-treated
sheep (CALP: +12.8  5.0%, P = 0.002; CALPSILD:
+9.7  4.3%, P = 0.006; Fig. 2A). The respective volume
was not significantly altered after tendon release in the
CONTROL group, but increased at 4 weeks compared
with baseline in both CALP (+21.1  7.7 cm3, P = 0.004)
and CALPSILD groups (+16.3  6.9 cm3, P = 0.010;
Fig. 3B).
Tendon release increases calpain activity,
which is blunted under calpeptin
administration
Calpain activity (Fig. 4A) increased at all assessed time
points compared with PRE in CONTROL (2 weeks:
Figure 3. Early atrophy after 2 weeks is explained by loss of slow myofibers. Volumes of the different tissue types assessed prior to, and 2, 4,
and 6 weeks after tendon release (A) Fiber volumes revealed that the loss of slow fibers was delayed by calpain inhibition while no quantitative
degradation of fast fibers was detected before 6 weeks. (B) Volumes of fatty and non-fatty connective tissue were altered similarly in the
CONTROL (n = 6) and the calpain inhibition groups (CALP, n = 5, CALPSILD, n = 6). Time effects: * P < 0.05, ** P < 0.01, *** P < 0.001
versus PRE; + P < 0.05, ++ P < 0.01, +++ P < 0.001 versus 2 weeks; & P < 0.05, && P < 0.01, &&& P < 0.001 versus 4 weeks. Indications above
columns refer to significant differences in total contractile tissue volume; indications inside columns refer to significant differences in the
specific fiber type volume. Columns are means + SD.
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+42.5  19.0 nmol L1 min1, P = 0.010; 4 weeks: +66.1
 34.1 nmol L1 min1, P = 0.006; 6 weeks: +60.6  20.7
nmol L1 min1, P = 0.032) and CALPSILD (2 weeks:
+58.7  51.5 nmol L1 min1, P = 0.001; 4 weeks:
+50.2  70.3 nmol L1 min1, P = 0.026; 6 weeks:
+61.7  74.4 nmol L1 min1, P = 0.030). In the CALP
group, a significant increase in calpain activity was only
detected at 6 weeks compared with baseline (2 weeks:
+22.6  21.9 nmol L1 min1, P = 0.169; 4 weeks: +42.2
 30.8 nmol L1 min1, P = 0.077; 6 weeks: +77.3 
78.6 nmol L1 min1, P = 0.015; Fig. 4A). Calpain activity
in the contralateral side remained unaffected (Fig. S1B).
Inhibition of calpain activity is counter-
regulated by increased calpain protein
content
Calpain 1 protein levels remained unaffected in the CON-
TROL group and were significantly increased in CALP
(+94.7  89.6%, P = 0.024) and CALPSILD
(+91.7  89.1%, P = 0.018) after 4 weeks. The increase at
6 weeks was statistically not significant (CALP:
+74.9  108.4%, P = 0.100; CALPSILD: +74.6  106.5%,
P = 0.075; Fig. 4B). Calpain 2 levels increased likewise in
the calpeptin-treated groups at 4 weeks (CALP:
+167.3  89.6%, P = 0.008; CALPSILD: +238.2  162.7%,
P < 0.001) with the CONTROL group remaining at baseline
level (Fig. 4C). At 6 weeks, calpain 2 levels increased in the
CONTROL (+249.8  234.2%, P = 0.006) and CALPSILD
groups (+234.8  170.4%, P = 0.009), but not in the CALP
group (+102.6  139.2%, P = 0.244; Fig. 4C). Representa-
tive western blot images are shown in Fig. 5.
Calpeptin prevents from the unloading-
induced decrease in relative FAK
phosphorylation and cleavage of talin
FAK (Fig. 6A) and FAK-pY397 (Fig. 6B) were variably
affected, leading to decreased specific FAK-pY397 levels
(FAK-pY397 per FAK) after tendon release in the CONTROL
group (2 weeks: 31.4  53.0%, P = 0.061; 4 weeks:
42.6  35.7%, P = 0.049; 6 weeks: 17.7  29.8%, P =
0.302), while it remained unaffected until 4 weeks and was
increased at 6 weeks in both CALP and CALPSILD (Fig. 6C).
Full length talin protein increased in the CONTROL
(4 weeks: +52.5  44.1%, P = 0.031; 6 weeks:
Figure 4. Blunting of calpain activity after tendon release is counter-regulated by increasing calpain protein concentrations. Calpain activity is
expressed as the change in concentration of the cleaved aminomethylcoumarin (AMCfree) per time. Protein levels were assessed in biopsy tissue
that was harvested prior to, and 2, 4, and 6 weeks after tendon release. (A) Tendon release increased calpain activity (CONTROL, n = 6), which
was blunted by calpeptin treatment alone (CALP, n = 5), but not in combination with sildenafil (CALPSILD, n = 6). (B) Calpain 1 and 2
concentrations were upregulated after 4 weeks in the calpeptin-treated groups only. Time effects: * P < 0.05, ** P < 0.01, *** P < 0.001
versus PRE; + P < 0.05 versus 2 weeks; & P < 0.05 versus 4 weeks. Group effects: # P < 0.05 versus CONTROL; $ P < 0.05 versus CALP. Bars
are means  SD.
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+128.2  61.0%, P < 0.001; compared with PRE) and
CALPSILD groups (4 weeks: +49.4  38.9%, P = 0.041;
6 weeks: +60.5  29.9%, P = 0.015; compared with PRE;
Fig. 7A) and the proteolytic 190 kDa fragment of talin
significantly increased in the CONTROL group after ten-
don release (2 weeks: +68.4  70.3%, P = 0.014; 4 weeks:
+156.4  177.9%, P = 0.011; 6 weeks: +261.1  217.5%,
P < 0.001; compared with PRE) which was prevented by
calpain inhibition (Fig. 7B). Gamma-vinculin levels
increased in the calpeptin-treated sheep at 4 weeks
(Fig. 7C). Meta-vinculin levels varied between sheep and
only the increase in the CONTROL group at 6 weeks was
statistically significant (+104.3  131.2%, P = 0.039,
compared with PRE; Fig. 7D).
PPAR-gamma isoforms 1 and 2 expression is
unaffected by calpain inhibition
PPAR-gamma 1 and 2 isoforms significantly increased in
all groups at all time points by at least +319% and
+186%, respectively, (Fig. 8).
Sildenafil increases intraocular pressure in
sheep
At 2 h after sildenafil administration, intraocular pressure
(pooled values of oculus dexter and oculus sinister) was
elevated (+2.1  2.2 mmHg, P = 0.004) and stayed above
resting level at 4 h (+2.2  1.5 mmHg, P = 0.005;
Fig. S2). A significant group difference was detected at
2 h compared with the untreated sheep (+2.1 mmHg,
P = 0.022). No side effects of sildenafil were observed.
Discussion
Recovery from a chronic RC tear still poses a clinical
challenge once muscle atrophy, myotendinous retraction,
and fat accumulation have established. This study tested a
novel approach to prevent atrophy and retraction after
RC tendon release in sheep with the hope to indicate a
new potential research orientation for the treatment of
human RC tears. We found that inhibition of the cal-
cium-activated protease calpain counteracted costamere
cleavage and delayed muscle atrophy, retraction, and
slow-to-fast phenotype shift until counter-regulation took
place by increased calpain 1 + 2 protein levels. This sug-
gests that the protease calpain may play an important role
in the early degradation of contractile tissue after RC ten-
don release in sheep.
Atrophy, retraction, and intramuscular fat content are
the best predictors for successful surgical repair and sub-
sequent recoverability of chronic RC tear (Bartolozzi et al.
1994; Goutallier et al. 1994; Thomazeau et al. 1997; Glad-
stone et al. 2007; Oh et al. 2009). This study demon-
strates that two of these three predictors can be tackled
by calpain inhibition. Atrophy was prevented for 2 weeks
Figure 5. Representative western blot images. Calpain 1, calpain 2, focal adhesion kinase (FAK), phosphorylated FAK (FAK-pY397), talin, gamma-
and meta-vinculin, PPAR-gamma 1 + 2 assessed in muscle tissue biopsied prior to, and 2, 4, and 6 weeks after surgical tendon release. The
contralateral control shoulder (CC) was biopsied at 6 weeks. This figure is assembled from two representative membranes per target protein.
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by treatment with calpeptin alone and in combination
with sildenafil (Fig. 1A). Microscopic measurements of
tissue composition revealed that the main reason for atro-
phy in the untreated sheep was the loss of slow fiber vol-
ume and that this deterioration was prevented with
calpain inhibition (Fig. 3B). The fiber degradation
machinery, that is the proteasome system, requires calpain
to disrupt structural anchors responsible for fiber integ-
rity, so that the disorganized sarcomeric filaments can be
ubiquitinated and digested (Smith and Dodd 2007; Goll
et al. 2008). This is supported by our assessments of talin,
a main structural anchor protein, which is cleaved into
the 190 kDa C-terminal proteolytic fragment by calpain
(Hayashi et al. 1999; Goll et al. 2003; Smith and Dodd
2007) and was shown previously in a rat model of hin-
dlimb unloading (Shenkman et al. 2015). The levels of
this talin fragment significantly increased with tendon
release alone, but not with concomitant inhibition of cal-
pain (Fig. 7B). Interestingly, the preventive effect of cal-
pain inhibition was abolished from 4 weeks onward,
when atrophy, characterized by a reduction in the slow
fiber portion, did not differ anymore between interven-
tion groups. At this time point, our data suggests that the
muscle overcame the inhibition by increasing calpain 1
and 2 enzyme levels (Fig. 4B + C). As already small
delays of repair may have a detrimental impact on func-
tional recovery in humans (Bassett and Cofield 1983;
Petersen and Murphy 2011), the delay of atrophy for
2 weeks may already be clinically relevant, but this needs
to be evaluated along with how this time window may
further be extended.
From 2 weeks onward, retraction (i.e., shortening of
the muscle-tendon complex) is simply the manifestation
of longitudinal atrophy and predominantly caused by
loss of sarcomeres in series (Jamali et al. 2000; Ward
et al. 2010), and thus may be explained by the same
mechanism that led to decreased total muscle volume.
The surprising finding is that calpeptin seemed to par-
tially mitigate shortening at a time when quantitative
loss of sarcomeres was not yet expected, that is, at
30 min after tendon release (Fig. 1B). Shortening at this
time point has been shown to be the result of acutely
decreased sarcomere length as opposed to sarcomere
number (Jamali et al. 2000). The mechanism by which
calpeptin may affect this acute retraction is largely
unknown. However, its capacity to lower intracellular
Figure 6. Calpain inhibition increases focal adhesion kinase (FAK) and FAK-pY397 concentrations after tendon release. Relative protein levels
were assessed prior to, and 2, 4, and 6 weeks after tendon release in calpeptin-treated (CALP, n = 5), calpeptin and sildenafil-treated
(CALPSILD, n = 6), and untreated sheep (CONTROL, n = 6). (A) FAK levels increased after tendon release. (B) FAK-pY397 levels increased with
calpain inhibition, but remained unchanged in the CONTROL group for the first 4 weeks. (C) Specific FAK-Y397 levels (FAK-pY397 per FAK)
decreased after tendon release, which was prevented by calpain inhibition. Time effects: * P < 0.05, ** P < 0.01, *** P < 0.001 versus PRE; +
P < 0.05 versus 2 weeks; & P < 0.05 versus 4 weeks. Group effects: # P < 0.05 versus CONTROL. Bars are means  SD.
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Ca2+ -concentration under circumstances where the sar-
comere is tetanically contracted (Chin and Allen 1996)
may play a role.
Two weeks of muscle unloading led to a slow-to-fast
shift of the muscle phenotype, which was prevented by
calpeptin (Fig. 2B). It is well documented that unloading
Figure 7. Calpain inhibition prevents cleavage of talin into a 190 kDa proteolytic fragment after tendon release. Relative protein levels assessed
prior to, and 2, 4, and 6 weeks after tendon release in calpeptin-treated (CALP, n = 5), calpeptin and sildenafil-treated (CALPSILD, n = 6), and
untreated sheep (CONTROL, n = 6). (A) The increase in full length talin was more pronounced in the CONTROL than in the treatment groups
despite a higher cleavage rate, which is indicative for an increased costamere turnover. (B) The cleaved C-terminal proteolytic 190 kDa
fragment of talin increased after tendon release and cleavage was prevented by calpain inhibition. (C) Gamma-vinculin, a main structural
protein of the costamere, altered similarly to FAK and may, together with full length talin, represent alterations in costamere abundance. (D)
Meta-vinculin was very variably expressed both at baseline and after tendon release. Time effects: * P < 0.05, *** P < 0.001 versus PRE; +
P < 0.05, ++ P < 0.01, +++ P < 0.001 versus 2 weeks; & P < 0.05, && P < 0.01 versus 4 weeks. Group effects: # P < 0.05, ## P < 0.01 versus
CONTROL. Bars are means  SD.
Figure 8. PPAR-gamma 1 and 2 protein levels increase after tendon release. Relative protein levels were assessed prior to, and 2, 4, and 6
weeks after tendon release in calpeptin-treated (CALP, n = 5), calpeptin and sildenafil-treated (CALPSILD, n = 6), and untreated sheep
(CONTROL, n = 6). Both (A) PPAR-gamma 1 and (B) PPAR-gamma 2 isoforms dramatically increased. Time effects: * P < 0.05, ** P < 0.01,
*** P < 0.001 versus PRE; + P < 0.05, ++P < 0.01 versus 2 weeks; & P < 0.05 versus 4 weeks. Bars are means  SD.
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leads to a change in MyHC isoform expression towards
fast muscle (Andersen and Aagaard 2000; Trappe et al.
2004; Biering-Sorensen et al. 2009) and it was reported
before, that modulating calpain activity may mitigate
slow-to-fast fiber conversion (Tidball and Spencer 2002).
Though the exact mechanisms remain unclear, we specu-
late that prevention of fiber type switch and atrophy went
hand in hand, as the thick type 1 myosin filament is
tightly embedded within the thin actin filaments and con-
nected to the Z-disk via titin (nota bene an excellent cal-
pain substrate (Goll et al. 2003)), and needed to be cut
free first in order to be replaced by a myosin type 2 fila-
ment. Furthermore, it is conceivable that calpeptin-
induced differences in Ca2+ concentrations (Chin and
Allen 1996) affected fiber type distribution via the CaN-
NFAT pathway (calcineurin - nuclear factor of activated
T cells) (Spangenburg and Booth 2003), or that calpeptin
itself had an unknown direct effect on the expression of
different MyHC isoforms. Like in atrophy, the preventive
effect of calpeptin was gone after 4 weeks, maybe because
calpain 1 + 2 enzyme concentrations doubled
(Fig. 4B+C). Intriguingly, the calculation of approximate
fiber volumes revealed that the fast fiber volume was not
significantly reduced until at least 4 weeks (Fig. 3B). The
fact that this was the case with and without calpeptin
treatment, suggests that the degradation machinery pre-
ferred to attack slow over fast fibers during tendon tear-
induced muscle disuse, at least for the first 4 weeks. It is
also possible that fast fiber digestion was compensated by
a slow-to-fast conversion of fibers, although slow/fast
hybrid fibers did not alter until 4 weeks and the seeming
increase at 6 weeks was statistically not confirmed
(Fig. 2B and 3B). Conversely, the loss of contractile tissue
between 4 and 6 weeks was predominantly explained by
decreased fast but not slow fiber volume. This observation
was independent of drug treatment and calpain concen-
trations (compare Fig 3B with 4B + C) and may indicate
that other processes which no longer reflect adaptations
to unloading, have started to degenerate the muscle,
because at 6 weeks, the typical unloading-induced slow-
to-fast conversion has stopped and the relative fast fiber
portion is surprisingly not different from PRE-values any-
more (Fig. 2B).
Aside from atrophy, a massive increase in intramuscular
fat content is observed in chronic RC tears. Also, the pathol-
ogy and time course behind this adaptation is still hotly
debated (Meyer and Ward 2016). Our recent study in sheep
suggested that fatty tissue decreases first before quantitative
accumulation occurs (Ruoss et al. 2017). Although the time
course in the present study pointed to the same direction
(Fig. 2A and 3A), this was statistically not confirmed, proba-
bly because the initial fat content was about 40% lower than
in the previously investigated sheep (Ruoss et al. 2017) and
therefore the potential for a relevant decrease was compro-
mised. However, we found that the isoforms 1 and 2 of the
adipocyte differentiation marker PPAR-gamma were
increased at 2–6 weeks after tendon release. PPAR-gamma 1
represents a composite increase in adipocytes, preadipocytes,
muscle-derived stem cells (MDSCs) and/or other cell types
(such as macrophages), and PPAR-gamma 2 indicates an
increase in mature adipocytes (Rosen and MacDougald
2006). Our PPAR-gamma assessments are not compatible
with the finding of little to no fat accumulation until
6 weeks (compare Fig. 8 with Fig. 2A + 3A). Either the
alterations of fatty tissue fraction assessed on oil red O
stained sections are below detection level, or PPAR-gamma
protein levels represent initiation of the adipocyte differenti-
ation machinery and the adipocytes are yet to come. Both
seem unlikely because Zhang and colleagues (Zhang et al.
2017) measured increased lipids using the oil red O tech-
nique already at 24 h after they induced fat cell differentia-
tion in isolated bovine MDSCs. Thus, further study is
needed to test the validity of PPAR-gamma as a marker for
fat cell differentiation in the ovine model of RC tears.
During myofibrillar turnover, calpains are known to
make a few very selective cleavages and leave the job of
quantitative degradation to the proteasome (Goll et al.
2008). Costamere components are amongst the target pro-
teins of calpain (Goll et al. 2003) and due to their role as
structural anchors for myofibers (Ervasti 2003), they may
significantly influence the rate of myofibrillar degradation.
We previously found that mitigating disruption of the
costamere (i.e., mitigating cleavage of talin and relative
dephosphorylation of the costamere-stabilising FAK with
anabolic steroids) may contribute to protection of contrac-
tile tissue after tendon release (Ruoss et al. 2017). The pre-
sent study now specifically addressed preservation of the
costamere complex through inhibition of calpain. Chronic
local calpeptin administration prevented from relative
dephosphorylation of FAK (Fig. 6C) and cleavage of talin
into the calpain-specific 190 kDa fragment (Fig. 7B). Inter-
estingly, the ex-vivo measurement of calpain activity was
not mirroring calpain protein expression (Fig. 4), probably
because regulation of calpain activity is a complex interplay
between intracellular Ca2+ dynamics, calpain autolysis, cal-
pastatin expression, and access to substrate (Goll et al.
2003). Furthermore, dynamics of other proteolytic systems
that can break down myofibrils, such as the caspases (trig-
gered by apoptotic signals) or the proteasome may affect
costamere and contractile tissue turnover.
Although this study successfully showed the efficacy of
calpain inhibition on atrophy in the ovine model of RC
tears, there were several limitations. In order to allocate
intervention effects of calpeptin (dissolved in 75%
DMSO), the CONTROL group had to receive 75%
DMSO. DMSO enhances membrane permeability by
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destabilizing the boundaries between the water and lipid
bilayer, and thus may exert effects itself on skeletal muscle
and its lipid content. However, compared to our recent
ovine study of RC tear (Ruoss et al. 2017), the CON-
TROL group did show a similar grade of atrophy, intra-
muscular fat, and FAK and talin dynamics at 2 weeks
after tendon release. Furthermore, the obtained biopsy
specimen does not necessarily represent the whole muscle.
Although the relative tissue distribution, calpain activity,
and protein quantification precisely represent the analyzed
piece of muscle, any extrapolations to the total volume
should be understood as approximate values. Lastly,
potential effects on skeletal muscle (and/or on the whole
organism) by calpain inhibition, by calpeptin itself enter-
ing the circulation, and by sildenafil are manifold. How-
ever, we did not observe decreased calpain activity in the
untreated contralateral shoulder (Fig. S1B). but many
potential (side) effects may have been missed.
Concluding, this study enriches the understanding of
early adaptations of RC muscle to simulated tendon tear
in sheep. There is evidence for an early calpain-mediated
degradation of the costameric attachments and of the
slow fibers. While during the first 2 weeks, atrophy does
not differ from adaptions to milder forms of unloading
(e.g., detraining), the typical slow-to-fast transformation
with unloading has stopped at 6 weeks, and contractile
tissue is lost to an extent that justifies the term “RC dis-
ease” although massive fat accumulation is not yet pre-
sent. Inhibition of calpain prevented the early unloading
adaptations, but not the subsequent initiation of RC dis-
ease. Further studies are needed to evaluate the clinical
potential of calpain inhibition to mitigate atrophy and
retraction, and to extend the time window before success-
ful repair and recovery from a RC tear turn impossible.
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